SAN
ANTONIO and IRVINE,
Calif., May 14, 2024 /PRNewswire/ -- CorePath
Laboratories has selected Genomic Testing Cooperative (GTC) as a
partner in next-generation sequencing (NGS) diagnostics for
hematologic neoplasms and solid tumors in a long-term
arrangement. Internalizing GTC's tests has enabled CorePath
pathologists to provide comprehensive evaluation of patient samples
combining targeted DNA and RNA profiling with integrated pathology
testing including morphology, immunohistochemistry (IHC), flow
cytometry, cytogenetics, and fluorescence in situ hybridization
(FISH) to provide accurate, timely and clinically useful
information to clinicians.
Cell-free based DNA and RNA (cfDNA and cfRNA) analysis,
supported by AI, allows CorePath to deliver a higher level of
oncology diagnostic, prognostic, and treatment information,
including presence or absence of EBV, HPV and TTV viral DNA/RNA,
HLA-A, B, and C genotyping and chromosomal structural gains and
losses. Additionally, liquid biopsy capabilities are
providing a non-invasive means for CorePath clinicians to monitor
therapy and detect a patient relapse without further surgery or
biopsy.
"NGS is not only important for selecting the proper therapy for
a specific patient but has become essential for complementing other
conventional diagnostic procedures in providing accurate diagnosis
and classification of various tumors, especially when RNA is
combined with DNA," stated Dr. Aamir
Ehsan, CEO and Founder of CorePath. "We are delighted
to be working with the GTC team on this and have found their
testing approach to be comprehensive, clinically focused, and
cost-effective," added Dr. Ehsan.
"With CorePath Laboratories' reputation for providing high
caliber, patient-centric pathology services, we are very glad to
have CorePath join the Co-Op network," stated Dr. Maher Albitar, CEO and CMO of GTC. "The Co-Op
NGS model is highly valuable in standardizing the generation of an
increasing volume of DNA and RNA data in oncology. With
internalization of NGS testing, Co-Op members can have immediate
access to a large database of RNA and DNA that facilitates
validation and clinical interpretation of testing results analyzed
by various machine learning algorithms (AI) that are developed and
trained using the same standardized data."
CorePath and GTC previously collaborated on a project, published
in The American Journal of Pathology, which demonstrated AI
could reliably make a differential diagnosis of both hematologic
and solid tumors using targeted transcriptomics.
DOI: 10.1016/j.ajpath.2022.09.006
About CorePath Laboratories
CorePath is a leader
in cancer diagnostics and one of the few national and international
laboratories with the ability to offer immunohistochemistry,
cytogenetics, FISH, PCR, multicolor flow cytometry, and next
generation sequencing at one location. CorePath is comprised of
academically trained board-certified pathologists and clinical lab
scientists helping providers care for their patients worldwide
through expertise, innovation, collaboration and integration.
CorePath is a Clinical Laboratory Improvement Amendments (CLIA) and
College of American Pathologists (CAP) accredited laboratory
headquartered in San Antonio, Texas.
For more information about CorePath, where innovation meets
empathy, visit www.corepath.us or contact us at
contact@corepath.us.
About Genomic Testing Cooperative, LCA
Genomic Testing Cooperative (GTC) is a privately-owned molecular
testing company located in Irvine,
CA. The company operates based on a cooperative (co-op)
business model. Members of the co-op hold type A shares with
voting rights. The company offers its patron members a full suite
of comprehensive genomic profiling based mainly on next generation
sequencing. Molecular alterations are identified based on
rigorous testing with the aid of specially developed algorithms to
increase accuracy and efficiency. The clinical relevance of the
detected alterations is pulled from numerous databases using
internally developed software. Relevance of findings to diagnosis,
prognosis, selecting therapy, and predicting outcome are reported
to members. The co-op model allows GTC to make the testing and
information platform available to members at a lower cost because
of a lower overhead. For more information, please visit
https://genomictestingcooperative.com/
Forward Looking Statements
All of the statements, expectations and assumptions contained in
this press release are forward-looking statements. Such
forward-looking statements are based on the GTC management's
current expectations and include statements regarding the value of
comprehensive genomic profiling, RNA profiling, DNA profiling,
algorithms, therapy, the ability of testing to provide clinically
useful information. All information in this press release is as of
the date of the release, and GTC undertakes no duty to update this
information unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corepath-laboratories-internalizes-genomic-testing-cooperatives-state-of-the-art-next-generation-sequencing-ngs-testing-for-solid-tumors-and-hematologic-neoplasms-302138858.html
SOURCE CorePath Laboratories